Loading…
BTMD
biote Corp.
NASDAQ· Healthcare· Medical Care Facilities· CUSIP 090683103
$1.57-3.68%Price as of Aug 29, 18:37 UTC · updated once a day, after the close
Key metrics
- Market cap
- $53.22M
- P/E
- 11.2x
- Forward P/E
- 3.5x
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- $0.14
- ROE
- —
- Profit margin
- 3.19%
- Revenue growth
- -9.50%
- Beta
- 1.65
- 52-week high
- $3.62
- 52-week low
- $1.27
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -87.5% over 5Y.
today you would have $125.32▼ -87.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.60 | $6.18 | $4.94 | $3.73 | $9.80 | |
| P/E | 38.0x | 3.5x | 68.7x | 38.0x | — | — |
| P/S | 0.9x | 0.5x | 1.1x | 0.7x | 1.3x | — |
| EPS | $0.74 | $0.09 | $0.13 | -$0.12 | — |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$3.50
Earnings growing 25.0% a year plus a 0.0% dividend — Lynch adds the yield to the growth rate, so a payer is not priced like a company that returns nothing. Growth capped at 25%.
Earnings
$3.14
Median P/E of 22.4 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
$12.08
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| COCHEnvoy Medical, Inc. | $0.69 | — | 14.4x | — | — | $53.27M |
| SCYXScynexis Inc | $5.39 | — | 0.8x | — | -18.38% | $53.63M |
| XTNTXtant Medical Holdings, Inc. | $0.38 | — | 1.3x | — | -25.16% | $53.87M |
| NTRBNutriBand Inc. | $4.46 |
About the company
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
- 223
- Irving, United States
Company description provided by Yahoo Finance.